Cyclophosphamide and cancer: golden anniversary
Top Cited Papers
- 29 September 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 6 (11) , 638-647
- https://doi.org/10.1038/nrclinonc.2009.146
Abstract
Cyclophosphamide remains one of the most successful and widely utilized antineoplastic drugs. Moreover, it is also a potent immunosuppressive agent and the most commonly used drug in blood and marrow transplantation (BMT). It was initially synthesized to selectively target cancer cells, although the hypothesized mechanism of tumor specificity (activation by cancer cell phosphamidases) transpired to be irrelevant to its activity. Nevertheless, cyclophosphamide's unique metabolism and inactivation by aldehyde dehydrogenase is responsible for its distinct cytotoxic properties. Differential cellular expression of aldehyde dehydrogenase has an effect on the anticancer therapeutic index and immunosuppressive properties of cyclophosphamide. This Review highlights the chemistry, pharmacology, clinical toxic effects and current clinical applications of cyclophosphamide in cancer and autoimmune disorders. We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases.Keywords
This publication has 108 references indexed in Scilit:
- High‐Dose Cyclophosphamide in the Treatment of Multiple SclerosisCNS Neuroscience & Therapeutics, 2009
- Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple SclerosisArchives of Neurology, 2008
- Rebooting the Immune System with High‐Dose Cyclophosphamide for Treatment of Refractory Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the EvidenceAmerican Journal of Ophthalmology, 2008
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Metabolism and Pharmacokinetics of OxazaphosphorinesClinical Pharmacokinetics, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Preparation of N-Phosphorylated Derivatives of Bis-β-chloroethylamine1aJournal of the American Chemical Society, 1954